01:34:12 EDT Tue 18 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:IMVT from 2020-05-19 to 2021-05-18 - 36 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-04-20 08:15U:IMVTNews ReleaseDEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-04-19 09:37U:IMVTNews ReleaseAPRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.
2021-04-01 03:47U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-03-31 02:45U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-03-29 22:27U:IMVTNews ReleaseROSEN, A TOP RANKED LAW FIRM, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors to Secure Counsel Before Important April 20 Deadline - IMVT, HSACU, HSAC, HSACW
2021-03-24 02:35U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-03-18 19:40U:IMVTNews ReleasePomerantz Law Firm Announces the Filing of a Class Action against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation and Certain Officers - IMVT; HSACU; HSAC; and HSACW
2021-03-18 17:25U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-03-18 09:47U:IMVTNews ReleaseIMVT SHAREHOLDER LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.
2021-03-17 13:03U:IMVTNews ReleaseINVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-03-12 04:20U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-03-08 19:45U:IMVTNews ReleaseIMVT BREAKING NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - IMVT, HSACU, HSAC, HSACW
2021-03-03 12:47U:IMVTNews ReleaseINVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-03-03 01:00U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-03-03 01:00U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW
2021-02-26 21:00U:IMVTNews ReleaseROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - IMVT, HSACU, HSAC, HSACW
2021-02-25 18:14U:IMVTNews ReleaseBREAKING ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors to Secure Counsel Before Important Deadline – IMVT, HSACU, HSAC, HSACW
2021-02-25 10:33U:IMVTNews ReleaseIMVT INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.
2021-02-23 10:00U:IMVTNews ReleaseIMVT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Immunovant, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
2021-02-19 21:06U:IMVTNews ReleasePomerantz Law Firm Announces the Filing of a Class Action against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation and Certain Officers - IMVT; HSACU; HSAC; and HSACW
2021-02-19 21:06U:IMVTNews ReleasePomerantz Law Firm Announces the Filing of a Class Action against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation and Certain Officers - IMVT; HSACU; HSAC; and HSACW
2021-02-16 08:00U:IMVTNews ReleaseImmunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020
2021-02-10 09:04U:IMVTNews ReleaseSHAREHOLDER INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
2021-02-04 20:49U:IMVTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunovant, Inc. - IMVT
2021-02-02 06:30U:IMVTNews ReleaseImmunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
2021-01-12 17:00U:IMVTNews ReleaseImmunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
2020-11-12 08:00U:IMVTNews ReleaseImmunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020
2020-10-20 10:25U:IMVTNews ReleaseSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
2020-09-04 16:01U:IMVTNews ReleaseImmunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters ’ Option to Purchase Additional Shares
2020-09-02 07:30U:IMVTNews ReleaseImmunovant Announces Pricing of Public Offering
2020-08-25 16:15U:IMVTNews ReleaseLigand OmniAb ® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
2020-08-25 07:30U:IMVTNews ReleaseImmunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
2020-08-24 08:00U:IMVTNews ReleaseImmunovant Appoints Michael Elliott Chief Scientific Officer
2020-08-13 12:59U:IMVTNews ReleaseSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
2020-08-12 16:01U:IMVTNews ReleaseImmunovant Reports Financial Results for the Quarter Ended June 30, 2020
2020-06-29 07:30U:IMVTNews ReleaseImmunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis